Q-omics provides the consensus-scored HTR2B profile across patient tissues and cancer cell-line models. HTR2B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HTR2B is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, HTR2B RNA expression shows 17,724 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where HTR2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR2B survival associations across molecular data types. HTR2B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR2B RNA expression–survival associations across cancer types. High HTR2B expression shows unfavorable associations in UVM, KIRP and STAD, but favorable associations in UCEC, LUAD and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for HTR2B RNA expression.
This table summarizes HTR2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HTR2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR2B shows lower tumor expression in KIRC, KICH, COAD, THCA and BLCA and higher tumor expression in LUAD. The KIRC box plot shows higher HTR2B RNA expression in normal versus tumor tissue (log2 FC = −1.103, t-test p < 0.001).
This table shows molecular features associated with HTR2B in patient tissues and cancer cell lines. In patient samples, HTR2B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HTR2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
